8-K filing — BIOLIFE SOLUTIONS INC (BLFS)
Filed: 2026-09-09 AccNo: 0001628280-26-061174 Size: 154 KB Item 8.01: Other Events
Stocks · News reference
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and expand global reach.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Benchmark Downgrades BioLife Solutions to Hold
Benchmark analyst Robert Wasserman downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold.
BioLife Solns Q2 Sales $28.466M Beat $27.683M Estimate
Halper Sadeh LLC is Investigating Whether UTZ, BLFS, NRIM are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties. Utz Brands is being acquired by Intersnack Group for $14.25 per share, BioLife Solutions is being sold to Repligen Corporation for $11.25 per share plus stock consideration, and Northrim BanCorp is merging with PBCO Financial Corporation. The firm is concerned that insiders may receive substantial benefits unavailable to ordinary shareholders and that transaction terms may limit competing offers.
8-K filing — REPLIGEN CORP (RGEN)
Filed: 2026-09-15 AccNo: 0001628280-26-062043 Size: 138 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable Biomanufacturing
The global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.